Duke noted that the prior-year second quarter had a lower baseline because of retaliatory tariffs. Updated OutlookFor the third quarter, Harvard Bioscience expects revenue of $21 million to $22.6 million, with a midpoint of $21.8 million representing approximately 6% year-over-year growth. Harvard Bioscience reaffirmed expected adjusted EBITDA growth of 6% to 10%. Management expects revenue growth, operating leverage and modest commercial restructuring actions completed in July to support that improvement. About Harvard Bioscience (NASDAQ:HBIO)Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide.